Main results
Thirty trials met the inclusion criteria. Twenty-three trials (77%) were of high quality, 24 trials (80%) were on acute low back pain. Four trials studied benzodiazepines, 11 non-benzodiazepines and two antispasticity muscle relaxants in comparison with placebo. Results showed that there is strong evidence that any of these muscle relaxants are more effective than placebo for patients with acute LBP on short-term pain relief. The pooled RR for non-benzodiazepines versus placebo after two to four days was 0.80 [95% CI; 0.71 to 0.89] for pain relief and 0.49 [95% CI; 0.25 to 0.95] for global efficacy. Adverse events, however, with a relative risk of 1.50 [95% CI; 1.14 to 1.98] were significantly more prevalent in patients receiving muscle relaxants and especially the central nervous system adverse effects (RR 2.04; 95% CI; 1.23 to 3.37). The various muscle relaxants were found to be similar in performance.
Authors' conclusions
Muscle relaxants are effective in the management of non-specific low back pain, but the adverse effects require that they be used with caution. Trials are needed that evaluate if muscle relaxants are more effective than analgesics or non-steroidal anti-inflammatory drugs.
P L A I N L A N G U A G E S U M M A R Y

Muscle relaxants for non-specific low-back pain
Muscle relaxants are effective for short-term symptomatic relief in patients with acute and chronic low back pain. However, the incidence of drowsiness, dizziness and other side effects is high. Muscle relaxants must be used with caution and it must be left to the discretion of the physician to weigh the pros and cons and to determine whether or not a specific patient is a suitable candidate for a course of muscle relaxants. Large high quality trials are needed that directly compare muscle relaxants to analgesics or NSAIDs and future studies should focus on reducing the incidence and severity of side effects.
